Esperion's ETC-1002 succeeds in Phase IIb, but Zetia combo could be key
This article was originally published in Scrip
Executive Summary
Esperion Therapeutics jumped 33.2% to $32.52 per share after the stock market closed on 1 October when the company revealed statistically significant reductions in LDL cholesterol for its lead drug candidate ETC-1002 versus the Merck & Co blockbuster Zetia (ezetimibe).